| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5457117 | LILLY | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride |
Jul, 2012
(11 years ago) | |
| USRE39049 | LILLY | Methods for inhibiting bone loss |
Jul, 2012
(11 years ago) | |
| US6906086 | LILLY | Methods for inhibiting bone loss |
Jul, 2012
(11 years ago) | |
| USRE38968 | LILLY | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
Jul, 2012
(11 years ago) | |
| US5393763 | LILLY | Methods for inhibiting bone loss |
Jul, 2012
(11 years ago) | |
| US5811120 | LILLY | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar, 2014
(10 years ago) | |
| US5972383 | LILLY | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar, 2014
(10 years ago) | |
| US5478847 | LILLY | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar, 2014
(10 years ago) | |
| USRE39050 | LILLY | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar, 2014
(10 years ago) | |
| US6458811 | LILLY | Benzothiophenes formulations containing same and methods |
Mar, 2017
(7 years ago) | |
| US6894064 | LILLY | Benzothiophenes, formulations containing same, and methods |
Mar, 2017
(7 years ago) | |
| US6797719 | LILLY | Benzothiophenes, formulations containing same, and methods |
Mar, 2017
(7 years ago) | |
| US8030330 | LILLY | Benzothiophenes, formulations containing same, and methods |
Mar, 2017
(7 years ago) | |
Evista is owned by Lilly.
Evista contains Raloxifene Hydrochloride.
Evista has a total of 13 drug patents out of which 13 drug patents have expired.
Expired drug patents of Evista are:
- US5457117
- USRE39049
- US6906086
- USRE38968
- US5393763
- US5811120
- US5972383
- US5478847
- USRE39050
- US6458811
- US6894064
- US6797719
- US8030330
Evista was authorised for market use on 09 December, 1997.
Evista is available in tablet;oral dosage forms.
Evista can be used as use for prevention of breast cancer, use for inhibiting bone resorption, treatment of osteoporosis in postmenopausal women, treatment or prevention of osteoporosis, prevention of osteoporosis in postmenopausal women.
The generics of Evista are possible to be released after 10 March, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 13, 2014 |
Drugs and Companies using RALOXIFENE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 1997
Treatment: Use for inhibiting bone resorption; Treatment of osteoporosis in postmenopausal women; Prevention of osteoporosis in postmenopausal women; Treatment or prevention of osteoporosis; Use for prevention o...
Dosage: TABLET;ORAL
EVISTA family patents
